Formalin-fixed paraffin-embedded (FFPE) tissue is widely used in translational research for its clinical relevance and accessibility. However, using FFPE samples in biomarker research presents technical challenges. Although FFPE preserves tissue morphology, nucleic acid quality can be compromised by fixation, embedding, storage, and extraction, potentially reducing material useability.
When you work with FFPE samples, assay selection is especially important if RNA degradation is present. Generating meaningful gene expression data depends on choosing a method compatible with the tissue’s quality and characteristics.
Why FFPE Samples Are Technically Difficult
FFPE processing prioritises preservation and tissue and cellular architecture over molecular integrity. Formalin fixation alters nucleic acids and proteins, and factors such as paraffin embedding, block age, storage, and retrieval/extraction methods further affect analyte quality. RNA is particularly vulnerable, as fragmentation can reduce transcript detection and limit assay sensitivity and suitability.
Challenges extend beyond RNA degradation. FFPE samples can vary in tumour content, stromal components, necrosis, inflammation, fixation time, tissue thickness, and available material. Small biopsies and archival blocks add pressure when multiple assays are required. Pre-analytical variability, including tissue handling and processing, can impact molecular performance before analysis even begins.
Researchers are often restricted by the suitability of the available sample, rather than which assay to use. A specimen may have enough material for analysis but still present limitations that affect interpretation.
FFPE sample quality is both a pathology and molecular challenge. While RNA quality metrics are useful, they do not replace assessment of tissue composition, lesion content, and region suitability. Pathology review remains essential for determining if a sample can support the research objective.
Why These Limitations Matter for Biomarker Research
Biomarker research relies on balancing biological signal with technical confidence. In FFPE bulk gene expression analysis, RNA fragmentation, limited material, and mixed tissue composition can affect sensitivity, reproducibility, and interpretation. Differential measurements between samples may result from true biology, variations in sample quality, or tissue composition. Without proper tissue context, these factors are difficult to distinguish.
These challenges are heightened when working with limited or irreplaceable samples, such as rare archival blocks, precious clinical trial biopsies destined for multiple analyses, or small lesions where additional material is unavailable. In these cases, each assay consumes material that cannot be replaced, making careful sample assessment and study planning essential.
The goal is not just to generate data, but to produce data that can confidently support scientific or development decisions. Informed selection is therefore a critical consideration. Broad discovery approaches, focused transcript panels, and spatial methods each answer different biological questions and should not be viewed as interchangeable. A sample may be entirely suitable for one biomarker objective while being unsuitable for another, depending on the required readout, input quality, and intended downstream application.
As biomarker programmes advance toward clinical development, these considerations become more important. Reproducibility requires documented sample selection, tissue assessment, appropriate controls, and an analytical strategy aligned with the intended decision.
Before selecting a gene expression platform for FFPE samples, it is important to understand both the limitations of the material and the type of data needed to answer the biological question. Sample quality, tissue composition, pathology review, assay choice, and downstream interpretation are interconnected in decision making rather than separate.
Where Targeted Expression Analysis Can Help
Targeted gene expression approaches are useful when FFPE samples are limited, degraded, or reserved for specific biomarker questions. The most appropriate platform depends on the biological question, required data output, available material, cost, complexity, and the level of resolution needed.
Bulk targeted expression methods, such as nCounter Analysis, are often chosen when the biological question is clearly defined and a consistent measurement of selected transcript targets is required. These approaches can be valuable when a study needs robust, focused gene expression data from FFPE material without the cost, complexity, or analysis burden of higher-resolution methods.
Spatial and single-cell approaches can provide additional biological resolution, including information about tissue architecture, cell localisation, and cellular heterogeneity. These methods may be appropriate when the research question requires spatial or cellular context, but they can involve greater cost, complexity, and data analysis requirements. The choice between bulk, spatial, and single-cell or single-nucleus methods should therefore be guided by what level of resolution is needed to answer the biomarker question.
However, targeted analysis does not replace the need for careful sample assessment. No technology can compensate for poor tissue selection, insufficient lesion content, inadequate study design, or a mismatch between assay and biological question. Effective FFPE workflows combine pathology review, tissue assessment, RNA quality evaluation, and analytical quality control. Together, these elements help ensure that molecular results can be interpreted within the correct biological context and support reliable and appropriate downstream conclusions.
In biomarker research, the key question is not whether a single platform can address every limitation in FFPE samples, but whether the selected assay is appropriate for the sample type, biological question, required data output, and intended downstream use. Method selection should support the study design rather than force unrealistic sample requirements or add unnecessary complexity to the sample collection protocol.
Reliable FFPE gene expression analysis requires careful sample assessment, pathology context, appropriate assay selection, and realistic expectations of what the material can support. When working with limited or valuable samples, aligning the specimen, technology, and biological question is often the most important step toward generating interpretable biomarker data.
Working with challenging or limited FFPE samples? Generating meaningful biomarker data starts long before an assay is run. Sample quality, tissue composition, assay selection, and study objectives all influence the reliability and interpretability of your results. Propath combines pathology expertise, rigorous quality control, and targeted gene expression analysis to help you maximise the value of precious tissue samples and generate data that supports confident scientific decisions. Contact our team to discuss your study and sample requirements.
